Key Takeaways A social media giant faltered on Thursday, Oct. 30, 2025, as artificial intelligence costs piled up, while a ...

Moderna (MRNA), with its widely used COVID-19 vaccine, rose to prominence during the global pandemic. The stock soared an eye ...

Moderna (NASDAQ:MRNA) stock surged as much as 12% Thursday following a STAT News report that the COVID-19 vaccine maker has been in discussions with at least one large pharmaceutical company about "a ...

Moderna ($MRNA) stock jumped 17% on Thursday, fueled by speculation of potential buyout talks amid concerns over declining ...

The vaccine, known as mRNA-1647, showed disappointing efficacy against primary CMV infection in healthy women, ranging from ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Small study looks only at a cardiac biomarker; findings are in line with reduced myocarditis risk in mRNA COVID vaccines ...

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moderna halts late-stage CMV vaccine trial after unmet goals but maintains 2025 financial outlook. Read more here.

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

Tesla (NASDAQ:TSLA) stock fell 3.6% after the electric vehicle manufacturer posted earnings that fell short of expectations, ...